欧州連合 - 英語 - EMA (European Medicines Agency)

leo pharma a/s - tacrolimus - dermatitis, atopic - other dermatological preparations - flare treatmentadults and adolescents (16 years of age and above)treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.children (two years of age and above)treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.maintenance treatmentmaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected).

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

leo pharma - betamethasone valerate; fusidic acid - cutaneous cream - 1mg/1gram ; 20mg/1gram

欧州連合 - 英語 - EMA (European Medicines Agency)

leo pharma a/s - brodalumab - psoriasis - immunosuppressants - kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

leo pharma - betamethasone valerate; fusidic acid - cutaneous cream - 1mg/1gram ; 20mg/1gram

欧州連合 - 英語 - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatitis, atopic - other dermatological preparations - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone valerate 0.1%{relative} (expressed as betamethasone);  ; fusidic acid 2%{relative} (hemihydrate, expressed as anhydrous fusidic acid);   - topical cream - active: betamethasone valerate 0.1%{relative} (expressed as betamethasone)   fusidic acid 2%{relative} (hemihydrate, expressed as anhydrous fusidic acid)   excipient: cetomacrogol 1000 cetostearyl alcohol chlorocresol liquid paraffin monobasic sodium phosphate dihydrate purified water sodium hydroxide white soft paraffin

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - sodium fusidate, quantity: 250 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; titanium dioxide; lactose monohydrate; crospovidone; hypromellose; microcrystalline cellulose; purified talc; magnesium stearate; dl-alpha-tocopherol - treatment of localised, as well as generalised, staphylococcal infections caused by susceptible organisms. in severe infections, deep-seated infections, infections due to methicillin-resistant staphylococci or when prolonged therapy may be required, fucidin must be given concurrently with other anti-staphylococcal antibiotic therapy.

ニュージーランド - 英語 - Medsafe (Medicines Safety Authority)

leo pharma limited - betamethasone dipropionate 0.5 mg/g;  ; calcipotriol 50 µg/g (as hydrate) - topical gel - 50 mcg - active: betamethasone dipropionate 0.5 mg/g   calcipotriol 50 µg/g (as hydrate) excipient: butylated hydroxytoluene hydrogenated castor oil liquid paraffin nitrogen polyoxypropylene monostearyl ether tocoferols - topical treatment of scalp psoriasis

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - ingenol mebutate -

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

leo pharma pty ltd - ingenol mebutate -